Conference Call with Dr. Lal Pathlabs Management and Analysts on Q3FY26 Performance and Outlook. Listen to the full earnings transcript.
Healthcare Services company Dr. Lal Pathlabs announced Q3FY26 results Revenue increased by 10.6% in Q3FY26 and by 10.8% for the nine months ended Dec’25. EBITDA (before exceptional items) for Q3FY26 increased by 16.3% with a margin of 27.2%. P&L; for Q3FY26 includes an exceptional impact of Rs 30.1 crore on account of Labour codes. PAT for Q3FY26 is Rs 91 crore. with a margin for of 13.9%. Interim Dividend of Rs. 3.5 per share for Q3FY26. Cash and Bank balances as on 31st Dec, 2025 is Rs. 1,411 crore. Result PDF